GlassScriptPhysician profile
Michael A Hughes
NPI 1194788331
$2,734.68
in general payments reported to CMS, 2019-2025
40 companies · $447 in 2025
The $447 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $834 · 2020: $190 · 2021: $545 · 2022: $362 · 2023: $296 · 2024: $60.68 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $803.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $236.15 | 2019-2020 | |
| Janssen Biotech, INC. | $224.92 | 2019-2025 | Carvykti, Darzalex, Talvey |
| Viewray Technologies INC | $201.07 | 2021 | |
| Novocure INC. | $200.17 | 2021-2025 | Optune, Optune Lua (Novottf-200t) |
| Galvanize Therapeutics, INC | $183.42 | 2023 | Aliya System |
| Amgen INC. | $169.12 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $131.01 | 2019-2025 | |
| Daiichi Sankyo INC. | $122.02 | 2019-2023 | Injectafer |
| Tersera Therapeutics LLC | $115.01 | 2019-2023 | Xermelo |
| Genzyme Corporation | $98.90 | 2019-2021 | |
| Abbvie INC. | $95.90 | 2020-2025 | |
| Incyte Corporation | $80.74 | 2019-2025 | Monjuvi |
| Regeneron Healthcare Solutions, INC. | $75.13 | 2019-2025 | Libtayo |
| Exelixis INC. | $72.49 | 2022-2025 | Cabometyx |
| Zap Surgical Systems, INC. | $68.40 | 2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hughes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.